We evaluated assays of Tissue Polypeptide Antigen in serum and urine, as an index to the presence of cancer. In the assay, serum, which is first absorbed with human albumin-labeled sheep erythrocytes, or untreated urine (diluted with an equal volume of TPA-free serum) is incubated with antibody specific to Tissue Polypeptide Antigen and then reacted with sheep erythrocytes labeled with Tissue Polypeptide Antigen. We found an increased con- Concentrations exceeding this were found in 2/67 (3%) sera and 6/56 (11 %) urines from supposedly normal persons. Tissue Polypeptide Antigen was found in above-normal concentrations in patients with cancer, regardless of neoplasm type and extension, with a higher proportion of abnormal values in patients with distal metastases.
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We evaluated assays of Tissue Polypeptide Antigen in serum and urine, as an index to the presence of cancer. In the assay, serum, which is first absorbed with human albumin-labeled sheep erythrocytes, or untreated urine (diluted with an equal volume of TPA-free serum) is incubated with antibody specific to Tissue Polypeptide Antigen and then reacted with sheep erythrocytes labeled with Tissue Polypeptide Antigen. We found an increased con- Concentrations exceeding this were found in 2/67 (3%) sera and 6/56 (11 %) urines from supposedly normal persons. Tissue Polypeptide Antigen was found in above-normal concentrations in patients with cancer, regardless of neoplasm type and extension, with a higher proportion of abnormal values in patients with distal metastases. 
Addftlonal
Reagents and Solutions
Serum, plasma, and urine specimens:
These were randomly obtained from specimens submitted for diagnostic purposes to our department.
The disease type and extent of cancer was established by careful review of the patients' medical history and confirmed by the histopathology of surgical or autopsy specimens.
Sheep erythrocytes:
These, in Alsever's solution, were obtained from the Hemoline Co., Denver, Cob. 80206. Urine specimens were stored in a freezer at -20 #{176}C within 1 h after collection. Sera were first warmed for 30 mm in a water bath set at 56 #{176}C, then frozen.
Sodium
Specimens were kept for as long as a month until processed.
Before the hemagglutination inhibition reaction, the urines were diluted with an equal volume of pooled human serum that on previous analysis showed no detectable TPA antigen (equal or less than 0.02 units per milliliter) or antibody. The sera were absorbed with an equal volume of packed erythrocytes (20 X 1O erythrocytes per milliliter) overnight, at 0-4 #{176}C. The following morning the sera were centrifuged for 30 mm and the supernatant fluid was stored at -20 #{176}C until assayed.
To check on the stability of the frozen samples, w did six experiments during one month, with use of a standard contaming 0.1 unit of TPA per milliliter, a negative control (0.03 unit/milliliter) obtained from a pool of serum from patients with benign neoplasms, and a positive control (0.5 unit/nil) obtained from a pool of serum from patients with cancer. The stability showed a variation of ±0.02 unit/milliliter.
Preparation of the Sheep Erythrocytes
At the beginning of each week the sheep erythrocytes in Alsever's medium are washed twice in 13 mmol/liter phosphate buffer, pH 6.8, containing 150 mmol of NaCl per liter. The erythrocytes are then diluted with this buffer to contain 1 X iO erythrocytes per milliliter. A portion of these cells is saved for use as controls and the remainder of them are "tanned" by diluting them with an equal volume of tannic acid solution (20-30 mg of tannic acid per milliliter of the buffer).
The tanned cells are gently stirred for 10 mm at 4#{176}C, washed once with a 13 mmol/liter phosphate buffer, pH 7.5, in 15 mmol/liter NaCl, and rediluted with buffer to contain 1 X io erythrocytes per milliliter. A portion of the tanned cells is saved for TPA labeling; the rest are used for albumin absorption of patients' samples.
The 
Selection of the Antibody Dilution
The evening before the assay, a standard titration plate is Results of assay of TPA with a "Microtiter U plate"
In this plate the top horizontalrow includes seven wells containingWA standard diluted between 1.5 to 0.02 unIt/mIllIlIter. The eighth well contains a negative or normal control (pool of human serum with low WA titer), the ninth well a 0.3 unit/milliliter standard, the tenth well is a 0.1 unIt/mIllIliter standard, and the eleventh well a positive (pool from human serum with a high WA titer). Each horizontal row thereafter Is used for dilution of patients' specimens. The first well in the patient row contains a control for the albumin-tagged erythrocytes (patient's serum or urine and tagged erythrocytes without antigen or antibody). Table 3 summarizes the relation of TPA concentrations in serum to the extent of disease. TPA concentrations in the range 0.13 to greater than 1.0 unit/milliliter were found in 71% of the patients with distal metastases, whereas such increases were found in 42% of patients who had no evidence of disease, 41% of those who had no known metastases, and 49% of those who had regional metastases.
CEA Determinations
TPA in Normal Persons and Patients with NonMalignant Tumors
Serum and urinary TPA values were increased in a variety of non-malignant diseases (Table 4) . Seven of 29 patients (24%) had TPA concentrations in their urine exceeding 0.09 unit/milliliter, as did 40 of 112 (36%) sera from patients, two of 67 (3%) sera from normal individuals, and six of 56 (11%) urines from the same normal persons. Comparison of TPA and CEA In Table 1 summarizes our preliminary studies. Supranormal concentrations were observed in the serum of 378 of 513 patients (74%) and in the urine of 49 of 77 patients (64%) with various carcinomas.
Results
TPA in Patients with Cancer
The carcinomas were divided into different groups according to sites of origin and the percentage of TPA elevations was reported. The diagnosis of disease was obtained from the patients' medical history and confirmed by histopathology. Table 2 shows the relation between extent of disease and results for serum and urine of patients with cancer. The patients were categorized by disease and then divided into four groups: those with previous cancer but with no evidence of disease at the time the specimen was obtained, those with no known metastases, those with regional metastases, and those with distal metastases. TPA was found to be increased irre- Gastrointestinal includes duodenum, lIver, pancreas,and stomach.
d Genitourinary includes bladder, kidney, prostate, testis, and urethra. Gynecological Includes cervix, uterus, and vagina. 'Head and neck includes esophagus, head, neck, eyelid, mouth, pharnyx, and tongue. 9 "Miscellaneous" includes basal cell, bone, salivary gland, thyroid gland, parotid gland, and sarcoma. patients with cancer and 53 patients with benign neoplasms. Of the patients with cancer, TPA was above normal in 69% and CEA in 42%. The concordance data for the cancer patients showed a correlation of 63%. Both assays were performed in 14 normal individuals; only one (7%) was found to have increased values for both TPA and CEA.
Discussion
TPA, a peptide in serum, has been suggested by Bj#{246}rklund as an index for identifying patients with cancer. Our data indicate that the antigen is present in abnormal concentrations ina relatively large proportion of patients with cancer, but also in a large proportion (36%) of patients with benign neoplasms. These data are similar to those originally reported by Bj#{246}rk-lund et aL, who found increased values for about 25% of patients with non-malignant diseases. We emphasize that our study only includes a single specimen from each patient. Bj#{246}rklund has stated that it is necessary to assay several sequentially collected specimens 
